Investor
Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 444 (CSE: $DOSE.C)
(OTC: $MJNA) (OTCQB: $AXIM)(CSE: $XCX.C)
Delta, Kelowna, BC, July 21, 2020 (Investorideas.com Newswire)
www.Investorideas.com, a global news source covering leading sectors including
marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
Read
this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/07211DOSE-MJNA-AXIM-XCX.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we look at a few public and private company announcements.
Rapid
Dose Therapeutics Corp. (CSE:
DOSE), a Canadian Life Sciences company focused on innovative
drug and active ingredient delivery solutions, announced that it
has begun COVID-19 vaccine research in conjunction with McMaster University and
the team lead by Drs. Alex Adronov, James Mahony, and Mark Larché. The
federally-funded project tests the use of QuickStrip™ for administering
vaccines orally as a convenient and safe alternative to injection with needles,
the currently accepted delivery format for most vaccines.
Dr. Adronov is a recognized Canadian
expert in synthetic polymer chemistry and the development of novel polymer
architectures, Dr. Mahony has extensive experience in virology and vaccine
development, and Dr. Larché is an immunologist with expertise in vaccine
research geared toward treatment of common allergies. The combined expertise of
this research team will enable development and evaluation of oral vaccine
delivery strategies.
Jason Lewis, RDT SVP said “RDT is
focused on novel research through collaboration with the experts at McMaster.
We see QuickStrip™, oral mucosa thin film delivery, as an efficient solution
for distributing vaccines globally. Experts believe that antigens to COVID and
other viruses can be delivered sublingually, a much easier and less expensive
process than the current single or multidose vial methods. Imagine the significance of creating a
vaccine that can be sent in an envelope, by mail.”
“Our combined experience indicates
that this is very feasible” said Dr. Adronov a recognized polymer expert
leading the research project. “Our past collaborations with RDT in developing
polymeric delivery innovations have resulted in solutions we are proud of, and
continue to be involved with. Globally, we are seeing the development of many
vaccines that we believe can be applied using sublingual delivery. Our project
focuses on producing a polymer strip that delivers viral antigens by a
transmucosal approach rather than injection. This funding will allow us to
quickly get started, and we expect to generate positive results in the near
future.”
Mark Upsdell, RDT CEO, said “The
current COVID situation requires everyone to think outside of the box as to how
we might deliver safe, effective and timely solutions for combating COVID-19
and other viruses that require serum-based defenses. RDT remains committed to
its research and innovation strategy which is highlighted now by our work on
the COVID-19 project’s unique delivery format. RDT provides scale-up testing
and bench strength support for the McMaster research team in the race to
provide an effective product that can be produced and delivered on a world-wide
scale. A successful outcome of this project and its application with our
QuickStrip™ delivery system will create exciting new opportunities for RDT.”
Medical
Marijuana, Inc. (OTC:
MJNA), the first-ever publicly traded cannabis company in
the United States that launched the world's first-ever cannabis-derived
nutraceutical products, brands and supply chain, announced
today that its investment company AXIM® Biotechnologies, Inc. (OTCQB:
AXIM) has announced the development of a rapid diagnostic
test measuring levels of functional neutralizing antibodies that are believed
to prevent SARS-CoV-2 (COVID-19) from infection.
Medical Marijuana, Inc. CEO Dr.
Stuart Titus commented: “Our portfolio is proud to see the innovation that AXIM
has showcased over the past few months and we are optimistic that this test
could help make a difference in achieving our end-goal of overcoming this
virus. Personally, I think that this kind of ingenuity will set us apart from
our competitors and allow us to continue to grow the other facets of our
business.”
Unlike currently available COVID-19
tests that detect an antibody response to the virus, AXIM’s rapid 10-minute
test measures a specific subpopulation of antibodies to block the virus from
attacking a person’s body. While there are expensive, time-consuming laboratory
tests that measure neutralizing antibodies, this test could be offered with
easier convenience, lower cost and much faster -- results in 10 minutes -- than
any other test on the market.
AXIM’s test could also help ensure
that vaccines elicit high levels of neutralizing antibodies. When a vaccine is
available, manufacturers can employ this test to evaluate its effectiveness in
vaccine recipients.
“We have succeeded at creating a
test that is cost-efficient, accurate and fast – hopefully serving as an
‘Immunity Passport™’ for vaccine developers as they begin larger Phase II and
III clinical trials,” AXIM® Biotech CEO John W. Huemoeller II said.
AXIM has filed a Pre-Emergency Use
Authorization and is compiling the necessary data from numerous tests recently
completed that are needed to apply for an EUA from the FDA. AXIM makes clear that while the Company
intends to file an EUA with the U.S. FDA, the U.S. FDA has not yet approved the
Company’s diagnostic test and there is no guarantee that any EUA once filed
will be approved.
AMP
German Cannabis Group Inc. (CSE:
XCX)
announced that it
has placed two orders for bulk and finished EU-GMP medical cannabis flower from
a Canadian Licensed Producer of medical cannabis. AMP will be purchasing and
importing to Germany, 50 kilograms of EU-GMP medical cannabis in September 2020
and a further 100 kilograms during January/February 2021. AMP and the Canadian
LP plan to expand the supply agreement for monthly large volume purchases of
medical cannabis as well as extracts.
The Canadian LP operates an indoor
growing and processing facility in Canada and was already EU-GMP certified by
German authorities earlier this year.
Dr. Stefan Feuerstein, President of
AMP, commented, "We are seeing a stronger than anticipated demand for
medical cannabis in the German marketplace and Canada is one of a few credible
suppliers to Germany in the short term. Demand from German pharmacies is so
high that AMP will be adding pharmaceutical distributors across Germany that
focuses solely on medical cannabis in the upcoming weeks. Our goal is to become
a major importer to Germany by the end of 2021"
NATIONS Cannabis, an
emerging Indigenous cannabis cultivation company and the Association of
Canadian Cannabis Retailers (ACCRES) share a common vision for a regulated
industry that ensures a safe supply and safe access to high quality
products – and have formalized their
alliance with the signing of a memorandum of
understanding.
The
MOU is the perfect marriage whereby NATIONS will provide a farm-to-store,
steady supply of cannabis products for the 26 members of the Association,
representing 65 retail stores. It also presents ACCRES with an opportunity to
incorporate a truly Indigenous brand into its fold with an ability to cultivate
new strains where market demands change. The projected value of the agreement
is $28 million in the first year, and $96 million by year three.
“The
partnership is pivotal in the evolution of NATIONS”, says the company’s
co-founder and Executive Chairman, Wes Sam. “We are unaware of any such
agreement involving an Indigenous production company in this province, and
ACCRES has identified our company as the first it has chosen to collaborate
with in this manner.”
From
the perspective of ACCRES, the deal is a win-win. “We believe NATIONS will
become the premier and earliest Indigenous cannabis producer in BC, “said
Association Interim President Mathew Greenwood. “They have a product that will
allow our retailers to differentiate themselves from others in the marketplace.
Furthermore, partnering with a company that gives an authentic voice to
Indigenous Peoples is an important aspect of this collaboration and will be
exciting for consumers.”
As
a late stage applicant in the federal licensing approval process, NATIONS’
momentum was halted this spring amidst the COVID-19 pandemic and construction
of its primary cultivation facility was paused. Once work resumes, the process
of seeking and securing a federal cultivation and processing license will also
continue.
“As
investors in the NATIONS’ project, we believe that the Agreement with ACCRES
represents real Indigenous economic reconciliation and participation in the
Cannabis industry,” said Chief Dan George, of the Burns Lake Band (Ts’il Kaz
Koh First Nation), adding, “We are excited to be part of this unique journey
with NATIONS and their partners.”
Upon
licensing approval by Health Canada, NATIONS hopes to actively begin the
process of facilitating a direct market arrangement with ACCRES and its
respective retailers. Licensing approval will also open the door to a potential
producer supply agreement through BC’s Liquor Distribution Branch.
For
more information about the Association of Canadian Cannabis Retailers, please
visit: https://accres.ca/
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big
Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and followers.
Contact management and IR of each company directly regarding specific
questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to
regulations of each country. Please read Investorideas.com privacy
policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Contact Investorideas.com
800
665 0411
No comments:
Post a Comment